Pre-school and school-aged children benefit from the switch from a sensor-augmented pump to an AndroidAPS hybrid closed loop: A retrospective analysis
Abstrakt
Data on closed loop systems in young children with type 1 diabetes (T1D) are limited. We tested the efficacy and safety of an open-source, do-it-yourself automated insulin delivery system AndroidAPS in preschool and school-aged children.
Research Design and Methods: This retrospective study analyzed diabetes control in 18 preschool (3-7 years) and 18 school-aged children (8-14 years) with T1D who switched from a sensor-augmented pump (SAP) to AndroidAPS. We compared the CGM parameters and HbA1c levels 3 months before and 6 months after the initiation of AndroidAPS therapy and evaluated frequency of severe adverse events during AndroidAPS use, the most frequent reasons for its interruption, and the experience and psychosocial benefits of AndroidAPS use.
General glycemic control was significantly improved after the switch from SAP to AndroidAPS. Time in range (TIR) increased in both preschool (70.8 to 78.6%, p = 0.004) and school-aged children (77.2 to 82.9%, p < 0.001), whereas HbA1c levels decreased (preschool children 53.8 to 48.5 mmol/mol, p < 0.001; school-aged children 52.6 to 45.1 mmol/mol, p = 0.001).
Time spent in range of 3.0-3.8 mmol/L increased slightly in school children (2.6 to 3.8%, p = 0.040), but not in preschool children (3.0 to 3.0%, p = 0.913). Time spent at <3 mmol/L remained unchanged in both preschool (0.95 to 0.67%, p = 0.432) and school-aged children (0.8 to 0.8%, p = 1.000).
No episodes of severe hypoglycemia or DKA and significant improvement of quality of life were reported by AndroidAPS users. AndroidAPS seems effective for T1D control both in preschool and school-age children but further validation by prospective studies is necessary.
